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Abstract
Background: The removal of high-abundance proteins from plasma is an efficient approach to investigating flow-
through proteins for biomarker discovery studies. Most depletion methods are based on multiple immunoaffinity
methods available commercially including LC columns and spin columns. Despite its usefulness, high-abundance
depletion has an intrinsic problem, the sponge effect, which should be assessed during depletion experiments.
Concurrently, the yield of depletion of high-abundance proteins must be monitored during the use of the
depletion column. To date, there is no reasonable technique for measuring the recovery of flow-through proteins
after depletion and assessing the capacity for capture of high-abundance proteins.
Results: In this study, we developed a method of measuring recovery yields of a multiple affinity removal system
column easily and rapidly using enhanced green fluorescence protein as an indicator of flow-through proteins.
Also, we monitored the capture efficiency through depletion of a high-abundance protein, albumin labeled with
fluorescein isothiocyanate.
Conclusion: This simple method can be applied easily to common high-abundance protein depletion methods,
effectively reducing experimental variations in biomarker discovery studies.
Background
Extracellular body fluids that contain plasma and serum
are the most valuable sources for biomarker discovery
and application, but useful protein biomarkers exist at
low concentrations (ng/ml or lower) in blood; approxi-
mately 30 high-abundance proteins constitute ~99% of
the total protein mass in human plasma, rendering the
detection of low-abundance proteins difficult. Several
methods have been developed to deplete high-abundance
proteins from blood, most of which are based on the
immunoaffinity of antibodies toward high-abundance
proteins, for example, multiple affinity removal system
(MARS, Agilent, CA, USA) columns which can remove
several specific high-abundance proteins [1-5], but some
reports have demonstrated that these systems incur pro-
blems, such as incomplete removal of high-abundance
proteins [3,6,7]. Recently, Bellei at al. showed that untar-
geted proteins are removed concomitantly [8] and
Chengjian et al. also reported that untargeted human
plasma proteins, such as alpha-1-acid glycoprotein 1,
alpha-1-acid glycoprotein 2, and alpha-1-antichymotryp-
sin, bind to MARS columns [9].
In fact, the reproducibility of the removal and recovery
of flow-through proteins is a critical aspect of high-
abundance protein depletion and although Veronica
et al. reported that in a triplicate 2-DE experiment, the
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any medium, provided the original work is properly cited.coefficient of variation (C.V.) of flow-through and bound
fractions by MARS depletion was 5.31% and 4.12%,
respectively, 3 depletions were not sufficient to validate
the reproducibility with regard to column life (200 times
is the minimum, as specified in the product manual of
the MARS column) [10]. Chengjian et al. observed that
after triplicate depletion of plasma, the capture effi-
ciency of high-abundance proteins exceeded 99% and
that 12 nontarget proteins were captured by the MARS
column–in particular, 100% of hemoglobin subunit
alpha and subunit beta were captured. Of the 12 nontar-
get proteins that were reported in Chengjian’s study,
several have important biological functions, such as
alpha-1-antichymotrypsin, which mediates rheumatoid
arthritis [11]. Therefore, capture efficiency and nonspe-
cific binding events should be monitored periodically or,
if needed, during every run. Yet, there is no convenient
quality monitoring process that monitors such para-
meters. Several techniques, such as bicinchoninic acid
(BCA) assay and enzyme-linked immunosorbent assay
(ELISA), have been used to determine the extent of
depletion [7,12], but post depletion experiments require
significant funds and time. Specifically, in biomarker dis-
covery or verification processes, hundreds of patient
plasma samples should be analyzed. If there is no effec-
tive quality monitoring step during the depletion of
hundreds of plasma samples, the resulting variations in
depletion can generate significant errors. One can deter-
mine approximately whether the depletion of plasma
has been performed correctly by observing the UV chro-
matogram of LC at 280 nm, but this chromatogram
does not yield accurate data on nontarget protein bind-
ing or target protein capture. Enhanced green fluores-
cence protein (EGFP) is a mutant of green fluorescence
protein (GFP), which has a maximum excitation wave-
length of 488 nm [13-15]. Its fluorescence is propor-
tional to its quantity, allowing one to measure its
concentration solely by measuring the UV absorbance.
We monitored the UV absorbance of several proteins,
including EGFP, to assess the performance and reprodu-
cibility of the depletion for high-abundance proteins in
blood
In this study, EGFP was expressed in an E. coli protein
expression system and purified, and a known amount of
EGFP was spiked into a clinical sample, such as plasma
or serum. During the depletion of high-abundance pro-
teins from plasma or serum, EGFP is an indicator of
flow-through proteins out of the MARS depletion col-
umn. EGFP exists stably in plasma, and EGFP monitor-
ing by UV absorbance at 488 nm (UV488 nm)p r o v i d e s
quality monitoring data on reproducibility and recovery
during depletion. In addition, one must track not only
the flow-through proteins but also the high-abundance
proteins that bind the antibody-based depletion column.
According to data from Agilent, buffer B, which is used
in the elution step, is based on urea; thus, Agilent has
specified that column performance is maintained up to
200 uses. Thus, during repeated use, depletion columns
capture fewer high-abundance proteins, and the life of
the column varies, depending on handling. Further, col-
umn performance cannot be monitored online. Routine
SDS-PAGE and Western blot or ELISA can be per-
formed to determine the efficacy of depletion. These
processes, however, take time and are costly.
In this study, we labeled human serum albumin (HSA),
the most abundant protein in plasma, with fluorescein iso-
thiocyanate (FITC) to monitor the capacity of a depletion
column. A known amount of FITC-labeled HSA (FITC-
HSA) was spiked into depleted plasma or depleted serum
as an indicator of high-abundance proteins. Because FITC
also has a maximum excitation at 488 nm, we measured
the depletion efficiency using EGFP for flow-through pro-
teins and FITC-HSA for high-abundance proteins by
online monitoring at UV488 nm during an HPLC run.
Thus, we developed a convenient method for measuring:
1. the recovery of flow-through proteins by monitoring
EGFP and 2. the removal of high-abundance proteins
using FITC-HSA at UV488 nm during depletion. This
online monitoring system conveniently tracks the recovery
and performance of all depletion systems that are run by
HPLC, including the MARS depletion column. In biomar-
ker discovery or verification steps, periodical online moni-
toring using EGFP or FITC-HSA assesses the quality of
depletion runs and identifies unsuitable cases from the
depletion runs, which can reduce experimental variation.
Materials and methods
Reagents
MARS columns (4.6 mm × 10 mm), solution A, and
solution B (Product No. 5185-5985) were provided from
Koreabiomics, a distributor for Agilent in Korea. There
are limited data on solutions A and B, which are based
on water with sodium azide and urea, respectively. For
FITC labeling, fluorescein isothiocyanate (FITC, Cat.
No. F7250-1G) and human serum albumin (HSA, Cat.
No. A1653-10G) were purchased from Sigma. PCR pri-
mers for EGFP were synthesized by CosmoGentech
(Seoul, Korea). LB media powder was purchased from
Biopure (Cat. No: LB407, Canada). Urea for 2DE-PAGE
was purchased from Amresco (Code: 0568-1KG, Ohio,
USA), and thiourea was obtained from GE Healthcare
( C a t .N o . :R P N 6 3 0 1 V ,U K ) .S o d i u mc a r b o n a t ef o rF I T C
labeling was purchased from Amresco (Code: 0585-
500G), and sodium thiosulfate was purchased from
Sigma (Cat. No.: S-7026). Other reagents that are not
mentioned here were obtained from Sigma.
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Human plasma samples were provided by Seoul National
University Hospital. All individuals provided informed
consent before being enrolled in this study, in accordance
with the approved protocol of the Institutional Review
Board at Seoul National University Hospital. To reduce
sampling bias due to individual variations, 100-μlp l a s m a
samples from 10 healthy persons (5 females and 5 males)
were pooled and centrifuged at 22,250 g at 4°C for 10
minutes to remove debris. The centrifuged plasma was
stored in 50-μl aliquots at -80°C until use. For the deple-
tion experiments, the plasma was thawed at 4°C.
Expression of enhanced green fluorescent protein
T h es e q u e n c eo fE G F Pw a so b t a i n e df r o mt h eL a b l i f e
website http://www.lablife.org. The entire EGFP coding
sequence (residues 1-231) was generated by PCR using
the vector pEGFP N1 (Clonetech, CA, USA) with the
sense primer 5’-G A C AAGCTTATATGGTGAGCA-3’
and the antisense primer 5’-GCCGGGATCACTCTC-
GAGCAC-3’. The underlined italic letters denote
HindIII and XhoI restriction sites, respectively, and the
bold letters are additional bases that generated an open-
reading frame. After digestion with each restriction
enzyme, gel extraction was performed, followed by liga-
tion into the prepared pET 24a (+) vector (Novagen,
WI, USA).
pET24a(+)-EGFP-His was transformed into BL21 RIL
codon-plus cells (DE3) (Novagen), and overnight culture
seeds of BL21-CodonPlus (DE3)-RIL that harbored the
EGFP DNA construct (5 ml) were used to inoculate 200
ml LB medium, containing kanamycin (30 μg/ml), and
grown overnight at 37°C. When the optical density of
the cells at 600 nm reached 1.0, protein expression was
induced by adding 0.5 mM isopropyl b-d-thiogalactopyr-
anoside (IPTG) at 21°C.
After overnight induction, cells were harvested by cen-
trifugation at 5,000 g for 10 min. Cell pellets were resus-
pended in ice-cold 20 mM Tris-HCl (pH 7.8),
containing 200 mM NaCl, 1 mM b-mercaptoethanol
(bME), and protease inhibitor cocktail (Roche, Switzer-
land). Resuspended cells were lysed by ultrasonication.
Cell supernatants were generated by centrifugation at
15,000 g for 20 min at 4°C. EGFP was purified by Ni-
NTA purification. Amounts of EGFP were measured by
BCA analysis and UV488 nm absorbance at the same
concentrations.
Determination of EGFP standard curve using UV488 nm
To construct a standard curve for EGFP, EGFP was seri-
ally diluted from 0 to 0.6 mg/ml (increments of 0.1 mg/
ml, 7 points) in MARS buffer A (Agilent, CA, USA).
Two hundred microliters of each diluted sample (blank,
20, 40, 60, 80, 100, and 120 μg EGFP) was transferred to
a 96-well plate (SPL, Korea) and read from 400 nm to
600 nm on an ELISA reader (PowerWave XS, Bio-Tek,
VT, USA); the standard curve was generated from
known amounts of EGFP, and the observed absorbance
at 488 nm was calculated by linear regression and R
2.
FITC-labeling of human serum albumin
One hundred micrograms of HSA (1.5 μmol) (MW:
66,472 Da, mature form) was dissolved in 20 ml of 100
mM sodium carbonate (pH 9.3), and 1.5 mg of FITC
(3.85 μmol) (M.W: 389.38 Da) was dissolved in 500 ml
dimethyl sulfoxide (DMSO, Cat. No: C6295, Sigma).
The solutions were mixed at a 1:2.56 molar ratio (HSA:
FITC = 1.5 μmol: 3.85 μmol) and incubated overnight at
4°C.
Solutions of FITC-HSA and unlabeled FITC were con-
centrated using a 5-kDa cutoff Centricon filter (Millipore,
MA, USA), dialyzed in Slide-A-Lyzer dialysis cassettes
(Pierce, Rockford, IL, USA) in 1 L PBS 5 times (the final
dialysis was done in 1 L PBS overnight), and reconcen-
trated on a 5-kDa cutoff Centricon filter (Millipore) to
remove unlabeled FITC. FITC-HSA was concentrated to
500 μl and purified on a Superdex S-200 gel filtration col-
umn by AKTA FPLC (Amersham Biosciences, Uppsala,
Sweden) to enhance the purity. A 30-cm Tricon column
(internal diameter: 10 mm, GE Healthcare) was used at a
flow rate of 0.3 ml/min. PBS was used as the buffer for
size-exclusion chromatography. After gel filtration, the
eluted fraction of pure FITC-HSA was pooled, concen-
trated to 1 mg/ml, and stored in the dark at 4°C until use.
Depletion of human plasma using MARS column
chromatography
To deplete plasma using the MARS column, plasma was
d i l u t e d5 - f o l dw i t hM A R Sb u f f e rAa n df i l t e r e do na
0.22-μm Ultrafree-MC Durapore centrifugal filter (Milli-
pore, Cat. No: UFC30GVNB). Plasma only, EGFP-spiked
plasma, and EGFP-only samples were applied to a MARS
column on an LC-10AT HPLC system (Shimadzu, Kyoto,
Japan), as described below. The sample loop volume of
HPLC was set to 100 μl, wherein 58 μlo f5 - f o l dd i l u t e d
plasma (total weight 2.32 mg) and 42 μl EGFP (final con-
centration of 0.3 mg/ml, total weight 300 μg) for EGFP-
spiked plasma or 58 μl MARS buffer A and 42 μlE G F P
(final concentration of 0.3 mg/ml, total weight of 300 μg)
for EGFP-only were injected into the MARS column.
The total LC run time of 45 min comprised the fol-
lowing sequence: 100% MARS buffer A at a flow rate of
0.7 ml/min for an initial 15 min, sample injection, a
15-min wash, 100% MARS buffer B at a flow rate of
1.0 ml/min for 5 min, and 100% MARS buffer A at a
flow rate of 0.7 ml/min for 10 min. The UV detector
was set to 280 nm for the injection of plasma only or
488 nm for the injection of EGFP-spiked plasma or
EGFP-only samples, and the eluted fractions were col-
lected in 500 μl. The flow-through and bound fractions
were eluted in 5 (total 2.5 ml) and 10 vials (total 5 ml),
respectively, for which the 2 eluted fractions were
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ml on a Centricon. After determining the concentration
of the fractions by BCA assay, the fractions was sub-
jected to Western blot, 1-DE, or 2-DE PAGE. The
resulting UV chromatograms were analyzed to deter-
mine peak areas and retention times.
To determine whether FITC-HSA, as an indicator of
high-abundance proteins was separable on a MARS col-
umn, 600 μg FITC-HSA was injected into a MARS col-
umn in triplicate while the UV detector was set to
488 nm. In addition, the depletion of FITC-HSA from
plasma was examined, wherein 600 μgF I T C - H S Aw a s
spiked into HSA-depleted plasma to simulate HSA-
undepleted plasma. The HSA-depleted plasma that was
spiked with FITC-HSA was injected into a MARS col-
umn in triplicate with the UV detector set to 488 nm.
The resulting UV chromatograms were analyzed to cal-
culate peak areas and retention times.
Calculation of EGFP concentration to determine the
recovery of depletion
For plasma depletion, the volumes of the unbound frac-
tion containing EGFP and the bound fraction were 2.5
ml and 5.0 ml, respectively. Each fraction was pooled
and concentrated to 1.0 ml on a Nanosep 3K centrifugal
filter (Pall Corporation, NY, USA). Next, 200 μlo ft h e
concentrated samples was transferred to 96-well plates
(SPL, Korea) to measure UV absorbance at 488 nm on
an ELISA reader, and the UV absorbance was extrapo-
lated on the standard curve to determine EGFP
concentration.
2-dimensional gel electrophoresis and silver staining
After plasma depletion, bound fractions that contained
high-abundance proteins were pooled and buffer-
exchanged with 5 ml of rehydration buffer (7 M urea, 2
M thiourea, 2% CHAPS, 60 mM DTT, and 0.5% (v/v)
pharmalyte (pH 3-10)) 5 times to remove any traces of
buffer B. After protein concentration was determined by
Bradford assay, 30 μg of bound fraction was subjected
to IEF using immobilized pH gradient (IPG) strips (7
cm, pH 4-7, linear gradient; Amersham Biosciences,
Sweden), as described [16]. Briefly, isoelectric focusing
was carried out on an IPG strip for 10,500 volt-hour at
20°C (500 volt in 1 hour, 4000 volts in 2.5 hours) using
an IPGphore system (Amersham Biosciences, Uppsala,
Sweden). Then, the strips were equilibrated for 30 min
in reducing solution (50 mM Tris-HCl (pH 8.8), 6 M
urea, 30% (v/v) glycerol, 2% (w/v) SDS, 1% (w/v) DTT)
and equilibrated for 30 min in alkylating solution,
which was the reducing solution plus 2.5% (w/v)
iodoacetamide.
Gel electrophoresis in the second dimension was per-
formed using a standard SDS-PAGE protocol. After
SDS-PAGE, protein spots were visualized by silver stain-
ing as described [17]. Briefly, after SDS-PAGE, the gel
was placed into fixation solution (40% MeOH, 10%
acetic acid) for 40 min and washed in 30% EtOH solu-
tion. After a sensitizing step with 0.02% sodium thiosul-
fate for 1 minute, the gel was washed twice in distilled
water for 30 sec. Silver reactions was performed with
0.2% silver nitrate and 0.02% formaldehyde (37% w/w)
solution for 20 min, and the gel was washed twice in
distilled water for 2 min. The gel was developed in 3%
sodium carbonate and 0.05% formaldehyde (37% w/w)
for 3 min and stopped using 0.5% glycine solution. The
stained gel was scanned on a UMAX PowerLook 2100
XL (UMAX Technologies, TX). The spots in the 2-DE
gel image was cut and in-gel digested; MALDI-TOF/
TOF (Model: 4700 Proteome Discovery, AppliedBiosys-
tems, Foster city, USA) analysis was performed to con-
firm the proteins as described (data not shown) [18].
Western blot analysis
For Western blot analysis, the concentrated bound frac-
tion in MARS buffer B was buffer-exchanged with 1 ml
MARS buffer A 10 times on a Nanosep 3K centrifugal
filter; MARS buffer B reacts with BCA solution to gen-
erate color. After BCA analysis, 5 μgw a ss e p a r a t e do n
12% SDS-PAGE gels and transferred to PVDF mem-
branes at 100 V (GE Healthcare, NJ, USA) for 1 hr at
4°C.
The membranes were blocked with 5% (w/v) BSA,
0.1% Tween 20 in TBS buffer for 2 hr at room tempera-
ture and incubated with primary antibodies on a shaker
at 4°C overnight. The primary antibodies were mouse
anti-human transferrin (1:1000; AbFrontier), mouse
anti-human alpha-1-antitrypsin (1:1000; AbFrontier),
mouse anti-human haptoglobin (1:1000; AbFrontier),
and rabbit anti-his probe (2:1000; Santa Cruz Biotech-
nology, CA, USA).
After being washed in 0.5% Tween 20 in TBS for 10
min 5 times, the membranes were incubated with horse-
radish peroxidase-conjugated secondary antibodies (goat
anti-mouse IgG-HRP for transferrin, alpha-1-antitrypsin,
and haptoglobin; and goat anti-rabbit IgG-HRP for
EGFP-His, Santa Cruz) at 1:5000 for 1 hr at room tem-
perature. Signals were detected using ECL Plus Western
Blotting Detection Reagents (GE Healthcare) on an
LAS-4000 Image analyzer (Fujifilm, Tokyo, Japan). Sig-
nals were analyzed quantitatively using image analysis
software (2D Phoretix expression v2004, Newcastle,
UK). All results were expressed as means and analyzed
statistically by Student’s t-test.
Results and Discussion
This study is divided into 4 sections, as described in
Figure 1. The first section comprises the preparation of
EGFP and generation of a standard curve using 7 points
of EGFP concentration and its corresponding UV absor-
bance at 488 nm (Figure 1A). In the second section,
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tor of flow-through proteins was depleted using a
MARS column, and Western blot was employed to
examine the performance of EGFP as an indicator (Fig-
ure 1B). In the third section, EGFP-only and EGFP-
spiked plasma samples were depleted every 20th run in
200 depletion experiments. Recovery of EGFP using
EGFP-only and EGFP-spiked plasma was measured
using UV absorbance at 488 nm to assess reproducibility
throughout the life (200 depletion runs) of a MARS col-
umn (Figure 1C). In the fourth section, FITC-HSA, as a
high-abundance protein indicator, was spiked into
depleted plasma, and high-abundance proteins were
depleted to determine the capture capacity of the MARS
column. For these 4 steps, commercial MARS columns
were used fewer than 200 runs, as recommended (user
manual, Agilent).
EGFP purification and FITC labeling of human serum
albumin
EGFP, with a C-terminal hexa-histidine tag, was
expressed in the BL21 (DE3) codon plus E. coli strain.
The yield of EGFP was approximately 50 mg/L in LB
media, and the purity was high, as shown by SDS-PAGE
(Figure 2).
To prepare FITC-HSA, HSA was labeled with FITC at a
ratio of 1:2.56, and the labeling efficiency was measured as
described in Additional file 1: Supplementary Figure 1. To
FITC-label HSA, the OD280 and OD495 of FITC-HSA and
FITC alone were measured; the labeling of HSA with
FITC was estimated as described in the FITC labeling pro-
tocol [19]. Consequently, the labeling ratio of HSA to
FITC was 1:2.61, based on the calculated value (Additional
file 1: Supplementary Figure 1), which approximates the
input value (1:2.56). Considering measurement errors,
FITC labeling of HSA proceeded nearly to completion;
thus, additional purification was not needed to separate
FITC-HSA from unlabeled HSA. The linearity of FITC
fluorescence was examined, based on the amounts of
FITC-HSA on increasing FITC-HSA levels, as described in
Additional file 1: Supplementary Figure 2. Apparently,
FITC fluorescence represented the corresponding
amounts of spiked FITC-HAS in the depletion samples.
Linearity between EGFP concentration and UV
absorbance at 488 nm
EGFP concentration was measured to examine the line-
arity of EGFP between 0.1 mg/ml and 0.6 mg/ml
(0.1-mg/ml intervals) versus UV absorbance at 488 nm
(Figure 3). EGFP concentration showed an excellent lin-
ear relationship versus UV absorbance at 488 nm, as
evidenced by R
2 = 0.9988 (Figure 3H). The limit of
quantitation (LOQ) of EGFP was 100 μg/ml (20 μg).
The concentration of EGFP, 300 μg/ml, was chosen for
further experiments, because it was in the middle of the
standard curve.
Figure 1 Schematic of experiments. (A) In the first stage, EGFP was purified, and the correlation between the quantity of EGFP and UV
absorbance at 488 nm was calculated. From these data, a standard curve was generated. (B) 300 μg EGFP was spiked into 2.21 mg of 5-fold-
diluted plasma, and MARS depletion was performed under UV488 nm monitoring in 6 repeat runs. Unbound and bound fractions were analyzed
by SDS-PAGE and 2-DE. In addition, Western blot was performed for EGFP, alpha-1-antitrypsin, transferring, and haptoglobin. The OD at 488 nm
was measured to determine the recovery of EGFP from EGFP-only and EGFP-spiked plasma. (C) During 200 runs of the MARS column, EGFP-only
or EGFP-spiked plasma was injected as an indicator of flow-through proteins for the quality assessment at every 20th run, in which the
reproducibility of depletion was calculated. (D) Depletions were performed using FITC-HSA as a high-abundance protein indicator to determine
the capture efficiency of high-abundance proteins.
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EGFP-only or EGFP-spiked plasma
To examine the reproducibility of EGFP as a flow-
through indicator in plasma, depletion experiments were
performed 6 consecutive times, wherein 58 μl of diluted
plasma (2.32 mg), spiked with 42 μl EGFP (300 μg), was
applied onto the MARS column. The chromatograms
for the 6 runs were reproducible with regard to reten-
tion time and UV intensity for EGFP-spiked plasma
(Figure 4A). The coefficient of variation (C.V.) was
0.08% for the retention time of the EGFP peak at 17
min (Additional file 1: Table S1).
A high-abundance protein fraction (30 μg) was sub-
jected to 2-DE and visualized by silver staining. In the
2-DE image, 6 high-abundance proteins were observed
(Figure 4B), consistent with a previous study [20,21].
The bound and unbound fractions in the 6 depletion
experiments were also examined by SDS-PAGE (Figure
4 C ) .T h en u m b e ra n ds h a p eo ft h eS D S - P A G Eb a n d s
were identical to those of a previous report [7]. Quanti-
tative analysis using SDS-PAGE band intensity was
attempted, but the gaps between the bands by SDS-
PAGE were too narrow, and some target bands over-
lapped with unidentified bands.
Next, we examined the efficacy of EGFP in MARS
column depletion by analyzing the bound and unbound
fractions of EGFP-spiked plasma. We assessed the effi-
cacy using Western blot by examining whether the
MARS column depleted representative high-abundance
proteins, such as a1-antitrypsin, haptoglobin, and
t r a n s f e r r i n ,b u ti td i dn o td e p l e t ef l o w - t h r o u g h
proteins, such as His-tagged EGFP (Figure 4D). Three
Figure 2 Cloning, overexpression, and purification of EGFP. (A) Map of pET24a (+)-EGFP-His, drawn with vector NTI software (version 6.0,
InforMax). The EGFP gene is designated by the gray arrow. (B) pET24a (+)-EGFP-His was transformed into BL21 RIL codon-plus (DE3) (Novagen)
and overexpressed by IPTG induction. Molecular weight marker (MW), uninduced total cell lysate (UN), induced total cell lysate (IN), and induced
supernatant (SPNT) were loaded on a 12% SDS-PAGE gel and visualized using Coomassie Brilliant Blue R250. (C) Purification was performed by
Ni-NTA, and the flow-through fraction (FT), wash fraction (W), and eluted fraction (EL) were run on a 12% SDS-PAGE gel. The EGFP-His band is
indicated with a black arrow.
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abundance proteins were selected for Western blot
analysis, because the silver-stained bands of albumin
and immunoglobulin by SDS-PAGE were adequately
visible. Anti-His was used to probe for EGFP, because
it contained a His-tag for purification purposes.
Because EGFP was not subject to depletion by the
MARS column, it should have been detected only in
the unbound fractions.
As shown in Figure 4D, EGFP was detected only in the
unbound fraction; thus, it did not experience the albumin
sponge effect [22,23] or carry over to the bound fraction.
Haptoglobin was nearly depleted from the unbound frac-
tion, but a1-antitrypsin and transferrin were not depleted
completely in the unbound fractions (Figure 4D). A small
amount of a1-antitrypsin in the unbound fraction can be
inferred due to the many a1-antitrypsin-homologous
proteins in the serpine family and the varying specificities
of the primary antibodies between suppliers. The inten-
sity of each Western blot band was analyzed and
expressed in bar graphs with standard error marks using
Phoretix gel analysis software (Figure 4E).
Reproducibility of depletion using EGFP-spiked plasma
and EGFP-only
We determined the reproducibility of depletion with
EGFP-only or EGFP-spiked plasma within the recom-
mended use of MARS columns (200 runs). Injection
samples were prepared identically in the 6 repeat experi-
ments as in the previous section (300 μg of EGFP and 2.62
mg of plasma protein in 100 μl). EGFP-spiked plasma was
injected into the MARS column every 20th run from the
20th to 200th run, and the resulting 10 chromatograms
were overlain, as shown in Figure 5A. For the EGFP-only
injection, 300 μg EGFP was injected every 20th run from
the 21st to 201st run, and the resulting 10 chromatograms
were overlain, as shown in Figure 5B.
In these UV chromatograms, the peak of unbound
fractions (flow-through proteins) appeared at 17 min,
and that of the bound fractions (high-abundance pro-
teins) appeared at 35 min in all 6 batches. The C.V. for
the peak area and retention time was 8.5% and 0.25%,
respectively, at 17 min (EGFP + other flow-through pro-
teins) during EGFP-spiked plasma depletion (Table 1);
the C.V. for the peak area and peak retention time was
5.7% and 0.75%, respectively, at 17 minutes (EGFP) in
EGFP-only depletion (Table 2). The C.V. values of the
bound fraction in both cases (EGFP-spiked plasma and
EGFP-only) were 23.2% and 36%, respectively. The high
variation in the bound fraction peak of spiked EGFP
was caused in part by a fluctuation in the 4th run, and
the variation in the bound fraction peak of EGFP-only
was due to instability of the UV detection, because the
peak at this retention time was from buffer, not pro-
teins. Two peaks at retention times of 36 min and
42 min also developed in all runs, but they did not
Figure 3 Linear correlation of UV488 nm versus EGFP concentration. EGFP was diluted from 0.1 mg/ml to 0.6 mg/ml in MARS buffer A in 0.1-
mg/ml increments, generating 7 concentration points. The UV absorbance of 200 μl of diluted sample was measured, ranging from 400 nm to
600 nm, on an ELISA reader. (A) Blank (MARS buffer A), (B) 0.1 mg/ml (20 μg), (C) 0.2 mg/ml (40 μg), (D) 0.3 mg/ml (60 μg), (E) 0.4 mg/ml (80
μg), (F) 0.5 mg/ml (100 μg), and (G) 0.6 mg/ml (120 μg). (H) Linear correlation of UV absorbance versus EGFP concentration was calculated by
linear regression. The correlation of coefficient (R
2) is 0.9988, as shown in the graph.
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Page 7 of 13Figure 4 Performance of EGFP from EGFP-only or EGFP-spiked plasma in depletion experiments. (A) Overlay of chromatograms from 6
consecutive MARS depletion runs using EGFP-spiked plasma. A mixture of flow-through proteins and EGFP as a flow-through protein indicator
were eluted as an unbound fraction at 17 min, and the high-abundance proteins were bound to the MARS column and eluted as the bound
fraction at 35 min. (B) Thirty micrograms of bound fraction (high-abundance proteins) was subjected to 2-DE for 7 cm from pH 4 to pH 7. Six
high-abundance proteins on a silver-stained gel were visualized, and MALDI-TOF/TOF analysis was performed to identify spots (data not shown).
(C) Equal amounts (5 μg) of plasma (P), unbound fraction (UB, flow-through proteins), and bound fraction (B, high-abundance proteins) from the
EGFP-spiked plasma depletion were run on an 8-12% SDS-PAGE gel and visualized by silver staining. The thick band at 25 kDa in the UB lane
constitutes spiked EGFP; there is no such band in the B lane. (D) The unbound fraction (UB) and bound fraction (B) were analyzed by Western
blot to detect target proteins. Anti-6×His tag was used to detect His-tagged EGFP, and antibodies for antitrypsin, haptoglobin, and transferrin
were used for the bound and unbound fractions from the 6 consecutive depletion runs. Serum albumin and immunoglobulin were excluded
from the Western blot due to their abundance. (E) Each protein in the Western blots was expressed as band intensity and shown on a bar
graph with standard errors, using the Phoretix gel analysis program. In the alpha-1-antitrypsin and transferrin results, there were traces of the
unbound fraction, which might have been caused by homology to the serpine family and other proteins.
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Page 8 of 13harbor proteins, because they were detected in the blank
run with an identical peak height and retention time
(Figure 5C). All runs in this study confirmed that deple-
tion by the MARS column is reproducible for up to 201
cycles. Figure 5D shows the SDS-PAGE analysis of the 6
depletion experiments after injection of EGFP-spiked
plasma for the flow-through and high-abundance pro-
tein fractions.
Recovery of depletion using EGFP as a flow-through
protein indicator
We examined the recovery of EGFP after the depletion
runs. The amount of EGFP that was spiked into the
plasma sample was adjusted to 300 μg. The volumes of
the EGFP-containing unbound fraction and bound frac-
tion were 2.5 ml (500 μl per vial, total 5 vials) and
5.0 ml (total 10 vials) after depletion, respectively. The
volumes of the 2 fractions were reduced to 1 ml by
Centricon, and the UV absorbance at 488 nm was mea-
sured using 200 μl of each concentrated sample to
estimate the concentration of EGFP, based on the stan-
dard curve (Figure 3). From the concentrations of both
fractions, the amounts of recovered EGFP in the
unbound and bound fractions were calculated. The
resulting EGFP quantities were compared with 300 μg
of input EGFP, wherein the recovery of EGFP can be
estimated in the unbound fraction after depletion.
The depletion recoveries using EGFP-spiked plasma
and EGFP-only were summarized every 20th run in
Tables 1 and 2. The average recovery of EGFP was
94.2% (1.7% of C.V.) for EGFP-spiked plasma (Table 1)
and 93.8% (2.6% of C.V.) for EGFP-only (Table 2).
Further, EGFP was detected only in the unbound frac-
tion; the bound fraction contained no traces of EGFP,
confirmed by SDE-SDS PAGE (Figure 5D). The loss in
EGFP for EGFP-spiked plasma (5.8%, 17.4 μg) and
EGFP-only (6.2%, 18.6 μg) might be attributed to accu-
mulated errors that were caused by several tube trans-
fers and volume reduction steps by Centricon. For these
losses, EGFP did not appear to remain in the MARS
Figure 5 Recovery using EGFP as a flow-through protein indicator. (A) Ten chromatograms from the 20th, 60th, 100th, 140th, 180
th,a n d
200th MARS column runs using EGFP-spiked plasma were overlain, and an overlay of 10 chromatograms from the 21st, 61st, 101st, 141st, 181st,
and 201st MARS column runs using EGFP-only was drawn in (B) using the same pattern. (C) One hundred microliters of MARS buffer A was
injected into the MARS column as the blank run. This spectrum at UV488 nm generated 2 peaks at 37 min and 43 min from the buffer
components. Thus, the 2 peaks were ignored in subsequent experiments. (D) Equal amounts (5 μg) of plasma (P), unbound fraction (UB), and
bound fraction (B) from the 20th, 80th, 100th, 140th, 180
th, and 200th runs from the 10 chromatograms were loaded onto an 8-12% SDS-PAGE
gel and visualized by silver staining. The bands at 25 kDa in the UB lane ere spiked EGFP; such bands were not detected in any other B lane.
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Page 9 of 13column after depletion, because the recovery rate of
EGFP was reproducible for the 6 consecutive plasma
depletion runs in the previous section (Additional file 1:
Supplementary Table S1).
Efficiency of depletion using FITC-HSA as an indicator of
high-abundance proteins
To examine the ability of the MARS column to capture
high-abundance proteins, FITC-HSA was used as an
Table 1 Recovery of EGFP in EGFP-spiked plasma using EGFP as a flow-through protein indicator
Run O.D488 nm
a) EGFP conc.
(mg/ml)
b)
Recovery (%)
c) Retention Time (min) Peak Area O.D488 nm
d) Retention Time (min) Peak Area
Unbound fraction Bound fraction
20 0.318 0.288 96.108 17.204 41318386 0.042 35.119 21663431
40 0.31 0.28 93.291 17.198 41864592 0.042 35.132 20405735
60 0.316 0.286 95.404 17.13 46612910 0.043 35.003 27522817
80 0.314 0.284 94.7 17.234 48029530 0.043 35.087 40458786
100 0.313 0.283 94.348 17.116 47410534 0.042 34.888 29504690
120 0.302 0.271 90.474 17.117 42958986 0.042 34.9 24795107
140 0.309 0.279 92.939 17.157 44253260 0.042 34.918 23585379
160 0.312 0.282 93.995 17.143 37695839 0.043 34.889 21280293
180 0.314 0.284 94.7 17.119 38865664 0.042 34.906 21914998
200 0.317 0.287 95.756 17.166 39476099 0.042 34.916 25579936
Average 0.313 0.283 94.172 17.158 42848580 0.042 34.976 25671117.2
S.D. 0.0047 0.0049 1.6456 0.042 3665255.437 0.0005 0.1 5954454.913
C.V.(%) 1.502 1.731 1.747 0.245 8.554 1.19 0.286 23.195
a) The unbound fractions were concentrated to 1 ml, for which the UV absorbance was measured at 488 nm.
b) EGFP concentration was calculated using the standard curve, as shown in Figure 3H.
c) EGFP recovery (%) = EGFP concentration/0.3 × 100.
d) The bound fractions were concentrated to 1 ml, for which the UV absorbance was measured at 488 nm.
EGFP-spiked plasma (300 μg of EGFP and 2.62 mg of plasma in 100 μl) was depleted every 20th run from runs 20 to 200. Ten chromatograms were analyzed to
calculate retention time and peak area. At the same time, unbound fraction and bound fraction from 10 independent depletions were concentrated to 1.0 ml,
and OD488 nm was measured to calculate recovery. Concentrations of EGFP in the unbound fraction and bound fraction were calculated according to the
standard curve, generated in Figure 3. The coefficient of variation (C.V. (%)) was calculated from the standard deviation, divided by the average and multiplied by
100. There was fluctuation in the 4th run, causing increase in C.V. (%) in the bound fraction peak area.
Table 2 Recovery of EGFP from EGFP-only solution using EGFP as a flow-through protein indicator
Run O.D488 nm
a) EGFP conc.
(mg/ml)
b)
Recovery (%)
c) Retention Time (min) Peak Area O.D488 nm
d) Retention Time (min) Peak Area
Unbound fraction Bound fraction
21 0.323 0.294 97.869 17.176 27072418 0.042 36.265 12098039
41 0.296 0.265 88.361 17.158 25303785 0.042 36.316 12924057
61 0.314 0.284 94.7 17.128 26898491 0.043 36.408 7177513
81 0.316 0.286 95.404 17.229 27372996 0.043 36.665 5887288
101 0.313 0.283 94.348 17.137 27712834 0.042 36.387 5351547
121 0.309 0.279 92.939 17.142 25688223 0.042 36.22 8400685
141 0.307 0.277 92.235 17.154 27835164 0.043 36.146 9345686
161 0.31 0.28 93.291 17.152 23774802 0.043 36.106 5814103
181 0.313 0.283 94.348 17.124 27535453 0.042 36.149 5474879
201 0.314 0.284 94.7 17.139 27848972 0.041 36.216 5325185
Average 0.312 0.281 93.819 17.154 26704313.8 0.042 36.288 7779898.2
S.D. 0.007 0.0074 2.4582 0.03 1353730.325 0.0007 0.167 2847817.672
C.V. (%) 2.244 2.633 2.62 0.175 5.69 1.667 0.46 36.605
a) The unbound fractions were concentrated to a volume of 1 ml, at which the UV absorbance was measured at 488 nm.
b) EGFP concentration was calculated using the standard curve, as shown in Figure 3H.
c) EGFP recovery (%) = EGFP concentration/0.3 × 100.
d) The bound fractions were concentrated to a volume of 1 ml, at which the UV absorbance was measured at 488 nm.
EGFP only (300 μg of EGFP and 100 μl of solution A) was depleted every 20th run from runs 21 to 201. Ten chromatograms were analyzed to calculate retention
time and peak area. All values were determined as in Table 1. The C.V. (%) of the peak area in bound fraction was high (36.6%), caused by variations in the 10
runs. These variations in peak area might have been due to the peaks at 36 min, which resulted from the buffer components.
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Page 10 of 13indicator of high-abundance proteins. FITC is detected
optimally at UV488 nm a n di su s e da sa ne x c e l l e n tp r o -
tein-labeling reagent. After purified HSA was labeled
with FITC, unlabeled, excess FITC molecules were
removed by buffer exchange and size-exclusion chroma-
tography. After SDS-PAGE using 10, 20, and 30 μgo f
purified FITC-HSA, the gel was exposed on a UV illu-
minator to assess the purity and mass of FITC-HSA,
based on fluorescence intensities (Figure 6A).
Although we purified FITC-HSA by gel filtration chro-
matography, several minor protein bands were observed
in the SDS-PAGE gel, considered to be accompanying
proteins that were carried by HSA. The fluorescence
intensities of 3 FITC-HSA bands showed good linearity
with 3 amounts of FITC-HSA (R
2 = 0.9908); the C.V. of
the fluorescence intensities for the 3 FITC-HSA bands
was 5.2% (Additional file 1: Supplementary Figure 2),
indicating that the quantitative linearity of fluorescence
intensities was excellent, based on FITC-HSA mass.
Next, 600 μg FITC-HSA was applied onto the MARS
column, and UV monitoring was performed at 280 nm
and 488 nm. Three repeat depletion experiments were
performed using FITC-HSA, which yielded nearly identical
UV absorption spectra at 280 nm and 488 nm (Figures 6B
&6C). FITC-HSA, bound to the MARS column, was
eluted at a retention time of 35 min. There was a small
peak at 17 min, which we considered to be unbound
FITC-HSA (Figures 6B & 6C), which might be attributed
to the unbound FITC-HSA that is caused by epitopes
blocking, which may be further described (Additional file
1: Supplementary Figure 3). Two peaks at 36 min and 42
min did not contain proteins, because they were also
detected in the blank run, as previously discussed.
To determine whether FITC-HSA is useful as a high-
abundance protein indicator in plasma, 6 high-abun-
dance proteins, including HSA, were depleted from
plasma using the MARS column, and the depleted
plasma was mixed with 600 μgF I T C - H S A –an amount
that presumably equals the HSA content in 16 μl
plasma, an identical volume in this study of which the
concentration was assumed to be 70 μg and the percen-
tage of HSA to be 50%. HSA was chosen as a represen-
tative of 6 high-abundance proteins, because HSA is the
most abundant protein; thus, it can be inferred that
HSA capture affects depletion quality preferentially.
The depleted plasma, containing FITC-HSA, was
applied onto the MARS column, and UV monitoring at
488 nm was performed 3 times (Figure 6D). The elution
patterns of 3 repeat runs were similar overall, whereas
the small peak between 18 min and 19 min was delayed
slightly in the second run compared with the first and
third (Figure 6D); it was ultimately considered to be a
minor variation. The peak at the retention time of 17
min in both experiments (FITC-HSA in Figures 6B & 6C
and depleted plasma containing FITC-HSA, Figure 6D)
reflected small amounts of unbound FITC-HSA. Because
there were no peaks in the unbound fraction in the blank
run (data not shown), we speculated that this phenom-
enon was caused by epitopes blocking in HSA by FITC
labeling, because MARS column function through anti-
body affinity.
When FITC is conjugated to HSA, the ability of the
MARS column resin to capture might decrease. Tagging
HSA with UV-detectable fluorescent proteins, such as
RFP (red) and CFP (blue), instead of FITC, might
increase the efficiency of monitoring the depletion of
high-abundance proteins.
Use of EGFP and FITC-HSA saves time and costs
EGFP can be cloned, expressed in an E. coli expression
system, and purified by NI-NTA affinity easily. A 1-L cul-
ture of E. coli can provide 50 mg of purified EGFP (data
was not shown), which can be used at least 150 times (300
μg per reaction); these steps cost under 300 USD (for
PCR-related products, LB media for E. coli culture, NI-
NTA resin, and imidazol for purification), and EGFP pre-
paration takes a week at most. If EGFP can be supplied as
a purified solution form or powder, more time can be
saved. The price of FITC powder (1 g) is approximately
200 USD, which can label 172 g HSA to be used at least
280,000 times (600 μg per reaction). HSA powder can be
purchased readily and costs approximately 280 USD.
FITC-HSA takes most 4 days to prepare, and using
EGFP and FITC-HSA renders the monitoring of deple-
tion processes in real time possible. In contrast, if an
ELISA kit or Western blot assay that has high sensitivity
but is not online or in real time is used to monitor
depletion, the initial costs (ELISA reader, etc.) might be
higher, and more time will be spent for post-monitoring
of depletion process. With regard to convenience and
cost, EGFP and FITC have an immeasurable advantage.
The percentage of EGFP that was spiked into plasma is
11.4% (300 μg EGFP in 2.62 mg of the plasma and EGFP
mixture), the level of middle abundance proteins in plasma.
Since it does not require a mass spectrometer, EGFP-
spiked plasma can be used periodically for quality monitor-
ing. In addition, this quantity of EGFP will not interfere
significantly with the MS analysis of low-abundance plasma
proteins. However, it will be recommended that EGFP
would be used to monitor flow-through proteins during
depletion rather than low-abundance proteins.
Based on this study, we recommend monitoring the
efficiency of depletion during the warranted use by the
column supplier, using EGFP and FITC-HSA to indicate
flow-through proteins and high-abundance proteins,
respectively. These indicators can also be used for online
monitoring that differentiates normal and abnormal
depletions to allow one to remove poor batches or
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Page 11 of 13replace the MARS column, as described in Additional file
1 :S u p p l e m e n t a r yF i g u r e4 .F I T C - H S Aw a su s e da sa
representative of high-abundant blood proteins that bind
to the MARS column, but one abundant protein might
not be enough to adequately evaluate the performance of
the column. Therefore, we will develop our approach
using additional abundant proteins such as alpha-1 anti-
trypsin or immunoglobulins in the MARS column.
Conclusions
We adopted EGFP as a flow-through protein indicator
and FITC-HSA as a high-abundance protein indicator to
monitor the recovery and efficiency during depletion of
high-abundance proteins from plasma or serum. This
system can also be applied to other high-abundance pro-
teins depletion systems. EGFP can be generated easily
from cloned EGFP, and FITC-HSA is also readily obtain-
able. HPLC systems are normally equipped with a UV
detector that can monitor UV absorbance of EGFP and
FITC-HSA, obviating the need to determine the recovery
and efficiency postexperimentally using expensive anti-
body-based tools, such as ELISA and Western blot. One
can determine the efficiency of recovery and reproduci-
bility online during depletion conveniently in this system.
Trivial amounts of FITC-HSA were not captured, pos-
s i b l yd u et ot h eb l o c k i n go fa n t i b o d ye p i t o p e sb yt h e
Figure 6 Depletion efficiency using FITC-labeled albumin as a high-abundance protein indicator. (A) Structural model of FITC-HSA, drawn
using Pymol software [24]. Using a protein databank file, HSA (PDB ID: 1E7I) was processed to be single molecule, and the backbone of HSA was
drawn in cartoon mode in magenta. Yellow circles indicate FITC on lysine residues. FITC-HSA (10, 20, and 30 μg) was subjected to SDS-PAGE (12%,
7 cm) and visualized under UV488 nm illumination without any staining. There were non-HSA protein bands in the lane, which were considered to
be HSA-binding proteins. (B) Three chromatograms at UV280 nm were overlain in the three repeated depletion runs using FITC-HSA as the high-
abundance protein indicator. (C) Three chromatograms at UV488 nm were overlain in the three repeated depletion runs using FITC-HSA as the high-
abundance protein indicator. (D) Three chromatograms at UV488 nm were overlain in the three repeated depletion using FITC-HSA-spiked depleted
plasma. The 6 most abundant proteins (HSA, immunoglobulin G, alpha-1-antitrypsin, immunoglobulin A, transferrin, and haptoglobin) were
depleted in prior and 600 μg of FITC-HSA was used to spike depleted plasma, which was intended to simulate real plasma. In (B), (C), and (D), there
were small unbound peaks at 17 min, which were considered to be the unbinding of FITC-HSA caused by epitopes blocking.
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Page 12 of 13FITC-labeled moiety, but these constant unbinding of
FITC-HSA were small and taking into these fact into
consideration would make analysis more accountable.
To overcome this phenomenon, we are attempting to
fuse fluorescent proteins with serum albumin, transfer-
rin, and antitrypsin as additional indicators of high-
abundance proteins. Although we have used only the
MARS column as a model system, our results suggest
that the 2 indicator proteins EGFP and FITC-labeled
albumin can be used conveniently to monitor the recov-
ery and efficiency of depletion from plasma or serum
using other types of immunoaffinity columns. In bio-
marker discovery, this process maintains the quality in
hundreds of plasma depletion runs.
Additional material
Additional file 1: Supplementary data. Four supplementary figures and
one table were included.
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